Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00425126 |
Recruitment Status
:
Completed
First Posted
: January 22, 2007
Last Update Posted
: May 27, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Delayed Graft Function | Drug: Epoetin Alfa | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 76 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation |
Study Start Date : | February 2007 |
Actual Primary Completion Date : | February 2010 |
Actual Study Completion Date : | February 2010 |

- Decrease in Delayed Graft Function

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients presenting for kidney transplantation
- Age > 18
- Deceased donor kidney transplant
Exclusion Criteria:
- History of thrombosis or hypercoagulable state
- Receiving Coumadin or Heparin
- Hemoglobin >=14 g/dl
- Uncontrolled hypertension

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00425126
United States, Pennsylvania | |
Allegheny General Hospital | |
Pittsburgh, Pennsylvania, United States, 15212 |
Principal Investigator: | Richard J Marcus, MD | West Penn Allegheny Health System |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00425126 History of Changes |
Other Study ID Numbers: |
RC-4044 |
First Posted: | January 22, 2007 Key Record Dates |
Last Update Posted: | May 27, 2010 |
Last Verified: | May 2010 |
Keywords provided by West Penn Allegheny Health System:
Delayed Graft Function Kidney Transplantation |
Additional relevant MeSH terms:
Delayed Graft Function Pathologic Processes Epoetin Alfa Hematinics |